Jun Watanabe

Jun Watanabe

Auto-generated profile, based on publicly available information

Jun Watanabe

UCB, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2021 in Parkinson's Disease
Verified
Journal Article
Open access
PDF file
YHYuka Hayashi
Yuka Hayashi
RNRyoko Nakagawa
Ryoko Nakagawa
MIMiwako Ishido
Miwako Ishido
YYYoko Yoshinaga
Yoko Yoshinaga
JWJun Watanabe
Jun Watanabe
YTYoshio Tsuboi
Yoshio Tsuboi
Introduction. Parkinson’s disease (PD) is characterized by a triad of motor symptoms and several nonmotor symptoms (NMS). Identifying the most appropriate treatment is essential for improving patient quality of life (QoL). However, it is still not known which PD symptoms more commonly affect patients with advanced PD (APD) versus non-APD. This study examined the factors that most affected the QoL of patients with APD (defined using the 5-2-1 criteria: ≥5 oral levodopa doses a day, off time ≥2 hours a day, or troublesome dyskinesia ≥1 hour a day) versus non-APD in a large Japanese population using the Japanese Quality-of-Life Survey of Parkinson’s Disease (JAQPAD) study. Methods. Participants in this self-reported survey-based study included all members of the Japan Parkinson’s Disease Association. Questionnaires assessing NMS and QoL (e.g., the 8-item PD Questionnaire [PDQ-8]) were included. Univariate and multivariate regression analyses were conducted to identify clinical factors impacting QoL using the PDQ-8 Summary Index (PDQ-8 SI). Results. Of the 3022 eligible patients, 864 were classified as having non-APD and 1599 as having APD. QoL as assessed by the PDQ-8 SI was notably worse in patients with APD versus non-APD (39.2 vs. 26.9, ). Although off time affected QoL only in patients with APD, PD duration and the NMS Questionnaire score significantly contributed to the QoL in both patients with APD and non-APD. Conclusions. This study identified the factors more commonly associated with worse QoL in patients with APD versus non-APD. Our findings offer new insights for providing optimal treatment and improving treatment satisfaction in patients with PD.

22 December 2021 in Parkinson's Disease
Verified
Journal Article
Open access
PDF file
HOHiromu Ogura
Hiromu Ogura
RNRyoko Nakagawa
Ryoko Nakagawa
MIMiwako Ishido
Miwako Ishido
YYYoko Yoshinaga
Yoko Yoshinaga
JWJun Watanabe
Jun Watanabe
YTYoshio Tsuboi
Yoshio Tsuboi
Background. Patients with Parkinson’s disease (PD) receiving levodopa treatment often report motor complications including wearing-off (WO), dyskinesia, and morning akinesia. As motor complications are associated with a decrease in patients’ quality of life (QoL), it is important to identify their occurrence and commence immediate management. This study investigated whether differences in the perception of motor complications exist between patients and their physicians in routine clinical practice. Methods. After an Internet-based screening survey, questionnaires were distributed to physicians and their patients in Japan. The 9-item Wearing-Off Questionnaire (WOQ-9) was used to objectively assess the presence of WO; patients with WOQ-9 scores ≥2 were considered to have WO. McNemar’s test was used to compare physician assessment versus WOQ-9 scores, patient self-awareness versus physician assessment, and patient self-awareness versus WOQ-9, separately. Morning akinesia and dyskinesia were assessed by both physician assessment and patient self-awareness with McNemar’s test. QoL was assessed using the 8-item Parkinson’s Disease Questionnaire (PDQ-8) with the Wilcoxon rank-sum test. Results. A total of 235 patients with PD and their 92 physicians participated in this survey. A significant discordance was observed between the WOQ-9 and physician assessment of WO (67.2% vs 46.0%; ). Furthermore, patient self-awareness of WO was 35.3% ( , vs physician). Morning akinesia (patient, 58.7%; physician, 48.9%; ), dyskinesia (patient, 34.0%; physician, 23.4%; ), and bodily discomfort (patient, 25.0; physician, 0.0; ) of QoL were underrecognized by physicians. Conclusions. This study investigated differences in the perception of WO between patients with PD and their physicians in routine clinical practice and highlighted that patients have a low awareness of the symptoms of WO compared with physician assessments and WOQ-9. Conversely, morning akinesia, dyskinesia, and bodily discomfort were underrecognized by physicians.

14 March 2023 in Movement Disorders Clinical Practice
Verified
Journal Article
Open access
KNKoichi Nagaki
Koichi Nagaki
RNRyoko Nakagawa
Ryoko Nakagawa
MIMiwako Ishido
Miwako Ishido
YYYoko Yoshinaga
Yoko Yoshinaga
JWJun Watanabe
Jun Watanabe
YTYoshio Tsuboi
Yoshio Tsuboi
Background: Parkinson's disease (PD) adversely affects the quality of life (QoL) of not only patients but also their caregivers.Objective: To determine the factors that most impact the QoL of family caregivers of patients with PD in a large Japanese population using data from the Japanese Quality‐of‐Life Survey of Parkinson's Disease (JAQPAD) study.Methods: Questionnaires, including the Parkinson's Disease Questionnaire‐Carer (PDQ‐Carer), were distributed to patients and their caregivers. Univariate and multivariate regression analyses were performed with the PDQ‐Carer Summary Index (SI) score as the dependent variable to determine the factors that impact caregiver QoL.Results: Overall, 1,346 caregivers were included in the analysis. Female sex, unemployment, caring for a patient with a high‐level need for nursing care, and a high Nonmotor Symptoms Questionnaire score were factors with a significant negative impact on caregiver QoL.Conclusion: Results from this study identified several factors that affect caregiver QoL in Japan.

27 September 2023 in Parkinson's Disease
Verified
Journal Article
Open access
PDF file
ATAtsushi Takeda
Atsushi Takeda
TBToru Baba
Toru Baba
JWJun Watanabe
Jun Watanabe
MNMasahiko Nakayama
Masahiko Nakayama
HHHiroyuki Hozawa
Hiroyuki Hozawa
MIMiwako Ishido
Miwako Ishido
Prescription doses of levodopa in patients with advanced Parkinson’s disease (PD) are generally lower in Japan than in the United States or Europe, although Japanese guidelines for the management of PD recommend increasing the dosage as the disease progresses. However, data regarding levodopa prescription practices in patients with advanced PD in the clinical setting are limited. This retrospective observational study analyzed patterns of drug use for patients with advanced PD in Japan using claims data from hospitalized patients in the Medical Data Vision Co. database. Eligible patients had at least two PD-associated claims in two different quarters between April 1, 2008, and November 30, 2018, and a 10-item activities of daily living score <60 upon hospital discharge (as a proxy for advanced PD). The primary endpoint was the prescribed dosage of levodopa at the index hospitalization. Dosages of other PD drugs (medications with an on-label indication for PD) and non-PD drugs were also assessed. Overall, 4029 patients met the inclusion criteria (mean age, 76.9 years; 83.3% aged ≥70 years). At the index date, 74.0% were receiving levodopa. Patients received a median of one PD drug in addition to levodopa, and 27.4% and 20.2% received one or two concomitant PD drugs, respectively. Patients received a median of two non-PD drugs. The median levodopa dosage and total levodopa equivalent dosage (LED) at the index hospitalization were 418.2 and 634.8 mg/day (adjusted for body weight, 9.0 and 13.7 mg/kg/day), respectively. The median levodopa and total LED dosage in each 6-month increment during the 5 years before and after the index date ranged between 263.9 and 330.2 mg/day (5.0 and 6.5 mg/kg/day) and 402.0 and 504.9 mg/day (8.3 and 10.1 mg/kg/day), respectively. This study suggests that many Japanese patients with advanced PD could receive more intensive treatment with higher doses of levodopa.

23 June 2025 in Advances in Therapy
Verified
Journal Article
Open access
AFAyataka Fujimoto
Ayataka Fujimoto
BQBing Qin
Bing Qin
DBDimitrios Bourikas
Dimitrios Bourikas
NDNajla Dickson
Najla Dickson
BMBrian Moseley
Brian Moseley
YIYushi Inoue
Yushi Inoue
This trial evaluated long-term safety, tolerability, and maintenance of efficacy of adjunctive brivaracetam (BRV) in Japanese and Chinese patients aged ≥ 16 years with focal-onset seizures (FOS). Interim analysis of data from EP0085 (NCT03250377), a long-term follow-up trial of adjunctive BRV 50-200 mg/day in Japanese and Chinese patients. Post hoc analyses assessed efficacy for 12- and 24-month completers and BRV retention. At data cutoff (June 1, 2023), 207 patients had enrolled; of these, 157 (75.8%) were ongoing and 50 (24.2%) had discontinued. Overall, 137 patients were 12-month completers and 63 were 24-month completers. Mean age was 36.7 years and 107 (51.7%) patients were female (100 [48.3%] male). Mean duration of epilepsy was 17.16 years. At data cutoff, total duration of BRV exposure was 378.5 patient-years. Mean duration of BRV exposure was 667.8 days (median 427.0 days), with a median modal dose of 200.0 mg/day (range 25.0-200.0 mg/day). Kaplan-Meier-estimated BRV retention rates at 12, 24, and 36 months were 85%, 76%, and 68%, respectively. Treatment-emergent adverse events (TEAEs) were reported by 184 (88.9%) patients, drug-related TEAEs by 60 (29.0%), serious TEAEs by 29 (14.0%), and 8 (3.9%) discontinued as a result of TEAEs. Median FOS frequency/28 days decreased from 7.59 during baseline to 4.11 during the evaluation period. For the overall evaluation period, 12-month, and 24-month completers, median percentage reductions from baseline in FOS frequency/28 days were 42.4%, 44.0%, and 38.9%, respectively, and 50% responder rates were 46.4%, 46.7%, and 38.1%. Based on this interim and post hoc analysis, long-term adjunctive BRV was well tolerated and efficacious in Japanese and Chinese patients with FOS. The efficacy response was maintained over time in those completing 12 and 24 months of trial participation. Overall, 68% of patients remained on BRV treatment for 3 years. ClinicalTrials.gov NCT03250377. Graphical abstract available for this article.

13 September 2025 in Advances in Therapy
Verified
Journal Article
Open access
NUNaotaka Usui
Naotaka Usui
DZDong Zhou
Dong Zhou
BQBing Qin
Bing Qin
STSomsak Tiamkao
Somsak Tiamkao
LCLeonor Cabral-Lim
Leonor Cabral-Lim
YIYushi Inoue
Yushi Inoue
We assessed the time course of treatment-emergent adverse events (TEAEs) in adult Asian patients (in Thailand, Japan, China, Philippines, Malaysia, Singapore, and Taiwan) with focal-onset seizures (FOS) during adjunctive brivaracetam (BRV) treatment. Post hoc analysis of EP0083/NCT03083665, a Phase 3, randomized, double-blind, placebo (PBO)-controlled trial that evaluated BRV 50 and 200 mg/day in adult Asian patients (≥ 16-80 years) with FOS. Following an 8-week prospective baseline, patients were randomized 1:1:1 to PBO, BRV 50 mg, or BRV 200 mg and entered a 12-week treatment period. Overall, 448 patients (mean age 34.5 years; 53.8% female) received ≥ 1 dose of trial medication (PBO/BRV 50 mg/BRV 200 mg: n = 149/151/148 [Safety Set]). The overall incidence of TEAEs was similar across treatment arms (53.6-58.1%), and most TEAEs were mild in intensity (45.0-48.3%). Patients discontinuing BRV because of TEAEs (1.3% BRV 50 mg; 2.7% BRV 200 mg) discontinued during the first 5 weeks of treatment (for PBO, discontinuations due to TEAEs [3.4%] took place between weeks 1-8). The incidence of drug-related TEAEs was 18.1% in patients receiving PBO, 24.5% in those on BRV 50 mg/day, and 39.2% for BRV 200 mg/day; however, most were of mild intensity and did not lead to BRV discontinuation. The incidence of TEAEs and drug-related TEAEs was highest during the first week of adjunctive BRV treatment and decreased thereafter. The onset of drug-related somnolence and dizziness occurred mainly during the first week of treatment. In Asian adults with FOS, most drug-related TEAEs were mild in intensity, indicating that adjunctive BRV had a favorable tolerability profile when initiated at a potentially therapeutic dose without titration. The incidence of drug-related TEAEs including somnolence and dizziness was highest during the first week of adjunctive BRV treatment, abating thereafter. These tolerability data could help inform patient monitoring and treatment decisions when prescribing BRV. ClinicalTrials.gov NCT03083665.